Vir Biotechnology, Inc. Common Stock
VIR Real Time Price USDRecent trades of VIR by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in VIR holdings by institutional investors
Quarterly net insider trading by VIR's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$50,000 Jul 20, 2026 Issue: Health Issues
-
$50,000 Apr 19, 2026 Issue: Health Issues
-
$50,000 Jan 17, 2026 Issue: Health Issues
-
$50,000 Oct 18, 2025 Issue: Health Issues
-
$50,000 Jul 18, 2025 Issue: Health Issues
-
$50,000 Apr 16, 2025 Issue: Health Issues
-
$50,000 Jan 19, 2025 Issue: Health Issues Government Issues Budget/Appropriations
-
$50,000 Oct 18, 2024 Issue: Budget/Appropriations Government Issues Health Issues
-
$50,000 Jul 14, 2024 Issue: Budget/Appropriations Government Issues Health Issues
-
$70,000 Nov 03, 2023 Issue: Trade (domestic/foreign) Taxation/Internal Revenue Code Medicare/Medicaid Science/Technology Health Issues
-
$140,000 Oct 20, 2023 Issue: Trade (domestic/foreign) Taxation/Internal Revenue Code Medicare/Medicaid Science/Technology Health Issues
-
$160,000 Jul 20, 2023 Issue: Trade (domestic/foreign) Taxation/Internal Revenue Code Medicare/Medicaid Science/Technology Health Issues
-
$150,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Science/Technology Health Issues
-
$140,000 Jul 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Science/Technology Health Issues
-
$170,000 Apr 20, 2022 Issue: Medicare/Medicaid Science/Technology Health Issues
-
$120,000 Jan 20, 2022 Issue: None
-
$170,000 Oct 20, 2021 Issue: None
-
$30,000 Jul 19, 2021 Issue: Health Issues
-
$90,000 Jul 18, 2021 Issue: Health Issues Government Issues
-
$30,000 Apr 20, 2021 Issue: Health Issues
-
$90,000 Apr 20, 2021 Issue: Health Issues Government Issues
-
$90,000 Jan 20, 2021 Issue: Budget/Appropriations Government Issues Health Issues
-
$30,000 Jan 19, 2021 Issue: Health Issues
-
$90,000 Oct 20, 2020 Issue: Health Issues Budget/Appropriations Government Issues
-
$90,000 Jul 19, 2020 Issue: Government Issues Health Issues
Former government officials who have lobbied for VIR
14 former government officials from 11 congressional offices at 3 lobbying firms have lobbied for VIR, most recently Jan 18, 2026.
-
Michael Williams House New Legislative Director, Rep. Lucy McBath (2021-2022); Legislative Assistant, Rep. Lucy McBath (2019-2020); Legislative Aide, Sen. Doug Jones (2019); Legislative Correspondent, Sen. Doug Jones (2018-2019) -
Arthur Sidney House New LD & Chief Counsel, Rep. Jackson Lee (2008-2009); Chief of staff and chief counsel, Rep. Johnson (2009-2020)
-
Adrienne Schweer Senate New Chief of Protocol, Office of the Secretary of Defense (2014-2016); Senior Aide and Director of Scheduling, Sen. Chuck Hagel (2006-2008); Staff Assistant, Sen. Chuck Hagel (2005) -
Paul Dioguardi Congress New Director, Office of Intergovernmental and External Affairs, U.S. Dept. of Health and Human Services (2009-2015); Chief of Staff, Office of Congressional and Intergovernmental Affairs, U.S. Dept. of Labor (1999-2001)
-
Douglas Stoss Congress New Cong. John Shadegg - Legislative Assistant, Subcommittee Staff Director, Chief of Staff, Policy Director; Centers for Medicare and Medicaid Services - Senior Counselor, Chief of Staff
-
Francesca Mccrary House New Legislative Assistant, Rep. Elijah Cummings (2016-2017); Professional Staff, House Oversight & Reform Committee (2016) -
Darren Willcox House New ​Asst. for Policy, Speaker Dennis Hastert; Admin. Asst., Legislative Director, Legislative Asst., Cong. Porter Goss; House Rules Comm. Assoc., Subcommittee Staff Director -
Derrick White Senate New Deputy Communications Director, Sen. Orrin Hatch (2000-2001)
VIR Estimated quarterly lobbying spending
VIR Revenue by Segment or Geography
New VIR patent grants
-
Patent Title: Combination hbv therapy Sep. 02, 2025
-
Patent Title: Hiv vaccines comprising one or more population episensus antigens Apr. 18, 2023
-
Patent Title: Hiv vaccines comprising one or more population episensus antigens Jan. 17, 2023
-
Patent Title: Antibodies against sars-cov-2 and methods of using the same Oct. 25, 2022
-
Patent Title: Antibodies against sars-cov-2 and methods of using the same Nov. 09, 2021
-
Patent Title: Hiv vaccines comprising one or more population episensus antigens Jan. 19, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded to VIR from public contracts
Recent insights relating to VIR
Recent picks made for VIR stock on CNBC
ETFs with the largest estimated holdings in VIR
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $VIR stock a Buy, Sell, or Hold?
- What is the price target for $VIR stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $VIR stock?
- Who owns the most shares of $VIR stock?
- What funds own $VIR stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view VIR Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
- Address San Francisco, CA
- Market Cap 1.8 billion
- Employees 367
- Industrial Classification Biological Products, (No Diagnostic Substances)
Vir Biotechnology, Inc. Common Stock (VIR) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for Vir Biotechnology, Inc. Common Stock (VIR).
Quiver Premium charts VIR's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at VIR, per a recent SEC DEF 14A filing. We estimate that the median employee at Vir Biotechnology, Inc. is paid $328,725.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|